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Abstract
Background: There is now good evidence that antiplatelet agents (principally low dose aspirin)
prevent pre-eclampsia, a leading cause of morbidity and mortality for pregnant women and their
babies. A Cochrane Review identified moderate, but clinically important, reductions in the relative
risks of pre-eclampsia (19%), preterm birth (7%) and perinatal mortality (16%) in women allocated
antiplatelets, rather than placebo or no antiplatelet.
Uncertainty remains, however, about whether some women (in terms of risk) benefit more than
others, what dose of aspirin is best and when in pregnancy treatment should ideally start. Rather
than undertake new trials, the best way to answer these questions is to utilise existing individual
patient data from women enrolled in each trial.
Methods/Design: Systematic review with meta-analysis based on individual patient data. This
involves the central collection, validation and re-analysis of thoroughly checked data from individual
women in all the available randomised trials.
The objective is to confirm that antiplatelet agents, given during pregnancy, will reduce the
incidence of pre-eclampsia. The review will then determine the size of this effect, and whether
antiplatelets delay the onset of pre-eclampsia or its impact on important outcomes for women and
their babies. It will also explore whether the effect of antiplatelets differs by womens' risk profile;
when commenced during pregnancy; and/or by dose.
Discussion: The PARIS (Perinatal Antiplatelet Review of International Studies) Collaboration has
been formed to undertake the review. This will be the first individual patient data review in the
perinatal field. Final results should be available by 2006–7.
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Background
Clinical significance of pre-eclampsia
World-wide, over half a million women die each year of
pregnancy related causes with 99% of these occurring in
low resource countries [1,2]. An estimated 10–15% of
these maternal deaths are associated with hypertensive
disorders of pregnancy [3].
High blood pressure is common during pregnancy:
approximately one in ten women will have their blood
pressure recorded as above normal at some point before
delivery [4]. For women who develop raised blood pres-
sure but have no other complications, pregnancy outcome
is similar to that for women with normal blood pressure.
Pre-eclampsia, a multi-system disorder of pregnancy usu-
ally associated with high blood pressure (hypertension)
and proteinuria, complicates 2–8% of pregnancies [5]. It
can affect the mother's organs, leading to problems in
liver, kidneys and brain, and to abnormalities of the clot-
ting system. As the placenta is also involved, there are
increased risks for the baby. The most common problems
are poor fetal growth due to inadequate blood supply
through the damaged placenta, and prematurity, related
either to the spontaneous onset of pre-term labour or the
need for an early, elective delivery.
Although the outcome for most women is good, pre-
eclampsia and eclampsia (the rare occurrence of seizures
superimposed on the syndrome of pre-eclampsia) are
major causes of maternal mortality. In low resource coun-
tries pre-eclampsia and eclampsia account for 10–15% of
maternal deaths [3] whilst in high resource countries pre-
eclampsia is consistently a leading cause of maternal mor-
tality [6,7]. Perinatal mortality is also increased [8,9].
There is little good quality information about morbidity
for either mother or baby, but it is likely that this too is
high. For example, pre-eclampsia accounts for about one
fifth of antenatal admissions [10], two thirds of referrals
to day care assessment units [11] and a quarter of obstetric
admissions to intensive care units [12]. Pre-eclampsia is
an antecedent for up to 19% of pre-term births [13] and
12% of growth restricted babies [14]. Also of note is the
high rate of intrauterine growth restriction (20–25%) in
pregnancies complicated by pre-eclampsia and the possi-
ble lifelong health effects due to prenatal programming
[15].
Pre-eclampsia is a multi-factorial condition. Although its
aetiology remains unclear, there have been significant
advances in the understanding of the pathophysiology of
the disorder. The primary lesion is thought to be deficient
trophoblast invasion of the maternal spiral arteries in the
second trimester, leading to underperfusion of the utero-
placental circulation and placental ischaemia [16]. The
resulting placental damage is thought to lead to release of
factors into the maternal circulation, which are responsi-
ble for the maternal syndrome. Activation of platelets and
the clotting system may occur early in the course of the
disease, before clinical symptoms develop [17,18]. Defi-
cient intravascular production of prostacyclin, a vasodila-
tor, with excessive production of thromboxane, a platelet-
derived vasoconstrictor and stimulant of platelet aggrega-
tion [19,20], have also been demonstrated to occur in pre-
eclampsia. These observations have led to the hypothesis
that antiplatelet agents, low dose aspirin (<300 mg/day)
in particular, might prevent or delay the development of
pre-eclampsia or reduce its severity and the risk of adverse
events.
It is further hypothesised that the effect of antiplatelets
may be different if treatment is started before placental
implantation is complete. [21]. If this hypothesis were
correct, the greatest benefit should be seen in women who
started treatment before 16 weeks gestation, with the
effect attenuating with later onset of treatment. Similarly,
it remains unclear as to the most appropriate dose of
antiplatelet therapy for the prevention of pre-eclampsia in
order to maximise benefits whilst minimising harms [22].
It has been suggested that low doses of aspirin may selec-
tively inhibit the cyclo-oxygenase pathway in platelet pro-
duction but not in vessel wall endothelium thereby
diminishing the synthesis of thromboxane but not of
prostacycline. A higher dose may inhibit both thrombox-
ane and prostacycline thereby neutralising the effect of the
intervention [20]. However, there is also limited evidence
from randomised trials that a higher dose of aspirin may
effect a greater reduction in the risk of pre-eclampsia [23].
Although it is known that pre-eclampsia is a multi-system
disorder, the relationship between the placental pathol-
ogy and maternal endothelial response is not fully under-
stood. Numerous maternal factors can predispose to the
disorder, such as previous pre-eclampsia, diabetes, renal
disease, chronic hypertension or other risk factors [24].
The syndrome known as pre-eclampsia may also be more
than one disease, each with distinct origins, pathologic
characteristics and natural history, rather than one funda-
mental process with varying degrees of clinical severity
[25,26]. Hence, the ability to assess the affect of antiplate-
lets on women with individual risk factors, or a series of
risk factors, is of great relevance to clinicians and women.
A meta-analysis based on data from individual women
will enable the exploration of these hypotheses.
Randomised trials of antiplatelet agents
The effects of antiplatelet agents were first evaluated in
small randomised trials, which reported striking reduc-
tions in the risk of hypertension and proteinuria [27-29].
These trials were too small to provide reliable information
about other more substantive outcomes, such as perinatalBMC Pregnancy and Childbirth 2005, 5:7 http://www.biomedcentral.com/1471-2393/5/7
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mortality and preterm birth. Also, there was no informa-
tion about the potential hazards of antiplatelet therapy,
such as a possible increased risk of bleeding for both the
woman and her baby, or possible effects on infant and
child development. The promising results of these early
trials led to several large studies around the world. Before
these could be completed, however, the use of low dose
aspirin had already become relatively widespread for
women considered at increased risk of pre-eclampsia.
Results of the larger trials were disappointing, as they
failed to confirm any statistically significant reductions in
substantive outcomes [30]. Nevertheless, the first
Cochrane Review of these trials demonstrated that, when
taken together, there are modest, but clinically important
benefits [31,32].
Summary of systematic review of aggregate data in 2004
The updated Cochrane Review identified 51 trials with
over 36,500 pregnant women evaluating antiplatelet
agents, principally low dose aspirin, for the prevention of
pre-eclampsia [23]. Nine of these trials included over
1000 women, and 15 involved less than 50 women. Fifty-
one studies were excluded, mostly due to the non-availa-
bility of clinically relevant data. Aggregate data from the
included trials demonstrated a 19% reduction (RR 0.81,
95% CI 0.75–0.88) in the risk of developing pre-eclamp-
sia associated with the use of antiplatelet agents, rather
than placebo or no antiplatelet. There was also a small
(7%) reduction in the risk of pre-term birth (RR 0.93, 95%
CI 0.89–0.98) and a 16% reduction in the risk of the baby
dying (RR 0.84 95% CI 0.74–0.96). Based on the average
risk of women included in these trials, about 70 women
would have to be treated to prevent one case of pre-
eclampsia, and 240 to prevent one baby death.
These effects are much smaller than had initially been
hoped for but, nevertheless, potentially they have consid-
erable public health importance. The conclusion from this
aggregate data review was that for most low-risk women
large numbers of women would need to be treated with
antiplatelets agents to prevent one episode of either pre-
eclampsia or perinatal death. Whether there are specific
high risk sub-groups of pregnant women for whom there
might be greater benefits, remains unclear, as does the
best time to initiate treatment, and at what dose. The aim
is now to extend this review based on aggregate data, to
utilise the available data for every individual woman in
each trial to help address these remaining questions.
The use of individual data for each woman will allow for
more powerful and flexible analysis of both subgroups
and outcomes [33,34]. This review will therefore provide
more specific information to guide the care of women at
risk of pre-eclampsia.
Limitations of the review using published, aggregate data
• Many studies were excluded because publications did
not report sufficient information to allow them to be
included in the review.
• The published aggregate data is variable in the complete-
ness of outcome reporting and in definitions used
between trials.
• The aggregate data meta-analyses were restricted to ana-
lysing outcomes for complete trials. As many trials
included women with a wide range of risk profiles at trial
entry, trials could only be defined by average values. Such
aggregated outcomes such as 'proportion of women devel-
oping pre-eclampsia' conceal a range of severity of disor-
der and so it was not possible to explore fully whether the
effectiveness of antiplatelet therapy differed according to
risk.
• It was also difficult to make precise recommendations
about when to start treatment. While most trials could
generally be classified as starting treatment at earlier or
later in gestational ages, there was a wide within-study
variation that could not be explored with aggregate data
analyses.
• There is a markedly skewed distribution of effect esti-
mates for each trial around the summary effect on pre-
eclampsia, with more small positive trials than small neg-
ative trials. This suggests the possibilities of publication
bias or that the differences in the characteristics of the
women enrolled in small and large studies has an impor-
tant influence on the effects of antiplatelet agents.
Ways of overcoming these limitations by using individual 
patient data
• Obtaining individual patient data from previously
excluded trials will allow assessment of whether these tri-
als are eligible for inclusion, both in terms of available
outcomes and methodological quality. This will poten-
tially increase the power and scope of the analyses.
• Trial level information obtained by direct discussion
with the trialists enables clarification of the definitions
and measurements used. Data for measured, but previ-
ously unreported, outcomes can also often be obtained
and trialists, who are part of a Collaborative group, may
be able to provide missing outcome data. Furthermore,
we will be able to apply common definitions across trials
based on each woman's baseline and clinical data. For
example, where possible, we will define pre-eclampsia
based on a set of uniform criteria.
• Subgroup analyses will be performed for a number of
different risk factors using individual patient's specific riskBMC Pregnancy and Childbirth 2005, 5:7 http://www.biomedcentral.com/1471-2393/5/7
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data, rather than using the aggregated risk profile of all
women enrolled in a particular trial.
• By obtaining gestational age at randomisation for each
individual woman, more precise patient-based analyses
can be performed exploring whether gestation at treat-
ment commencement alters the effectiveness of
antiplatelets.
• Formation of a Collaborative group, is likely to lead to a
more complete identification of all relevant trials, includ-
ing those previously unpublished. This may help over-
come the potential for publication bias. The patient-level
data will also allow us to explore whether there were
important differences in the characteristics of women
enrolled in small and large trials.
Methods/design
Objectives
The objective of this review is to confirm that antiplatelet
agents, given during pregnancy, reduce the incidence of
pre-eclampsia. The review will then determine the size of
this effect, and whether antiplatelets reduce the severity of
pre-eclampsia and/or its impact on important outcomes
for women and their babies. It will also explore whether
the effect of antiplatelets differs by womens' risk profile,
when commenced during pregnancy, and/or by dose.
The main questions to be addressed in this review are:
• Do antiplatelet agents, primarily low dose aspirin, have
clinically important benefits for women at risk of develop-
ing pre-eclampsia and their babies?
Investigation of this hypothesis will also explore whether
the treatment effect differs, in a clinically meaningful way,
between women with different risk factors such as those
with a history of early onset pre-eclampsia, renal disease,
diabetes, chronic hypertension, or autoimmune disease.
• Does the planned dose of aspirin affect outcome in
terms of preventing or delaying the onset of pre-eclampsia
or other adverse outcomes, such as preterm birth or peri-
natal death?
• Do the effects of aspirin differ according to gestation at
onset of treatment?
Identifying studies
The search strategy to identify potentially eligible studies
will include a search of the register of trials developed and
maintained by the Cochrane Collaboration Pregnancy
and Childbirth Review Group. Details of how this register
is maintained are available elsewhere [35,36], but it
involves extensive searching of bibliographic databases
such as MEDLINE, The Cochrane Controlled Trials Register
and hand searching of relevant journals. Trialists will be
asked if they know of any further studies. [See Additional
file 1] for the list of trials potentially eligible for inclusion.
In addition, all members of the Collaborative Group will
be asked to notify any unpublished trials of which they are
aware.
Inclusion and exclusion criteria for studies
The inclusion and exclusion criteria for the types of study
designs, participants, interventions and data complete-
ness to be included in the review are listed below. Each
potentially eligible study will be assessed independently
by two members of the Secretariat, unblinded to the trial's
identity. Any differences of opinion regarding the assess-
ment of the inclusion criteria will be resolved by discus-
sion between the two assessors. If differences cannot be
resolved, a third member of the Secretariat will be asked
to assess the study. If individual patient data are unavaila-
ble from an eligible trial, the trial will remain included in
the review and aggregate data will be used.
a. Study design
Studies will be included in the review if they were ran-
domised trials. Quasi-random study designs, such as
those using alternate allocation, will be excluded. The
level of allocation concealment within each trial will be
assessed according to the criteria outlined in the Cochrane
Handbook [37], and classified as either adequate, unclear
or clearly inadequate. These assessments will be made
together with the outcomes of thorough data checking
procedures.
b. Participants
Participants will be pregnant women at risk of developing
pre-eclampsia. Women who started treatment postpartum
will be excluded, as will those who already have a diagno-
sis of pre-eclampsia at trial entry (defined as hypertension
with new onset proteinuria after 20 weeks gestation, not
due to renal disease).
c. Interventions
The interventions will be any comparisons of an antiplate-
let agent (such as low dose aspirin or dipyridamole), or
any combination of antiplatelet agents, compared with
placebo or no antiplatelet agent. This is regardless of dose,
mode of administration and irrespective of whether the
antiplatelet is in combination with another drug. Trials
that assessed only physiological outcomes following a
short duration of intended therapy will be excluded.
d. Completeness of follow-up
The main analyses will include all trials that fulfill the pre-
vious inclusion criteria, regardless of completeness of fol-
low-up. Sensitivity analyses will be undertaken to assessBMC Pregnancy and Childbirth 2005, 5:7 http://www.biomedcentral.com/1471-2393/5/7
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the effect of the inclusion of data from trials where only
small numbers of enrolled participants have available
outcome data. The threshold for an acceptable level of
data completeness may vary by outcome. For example, for
long-term follow-up of women and children, data may be
included if follow-up was less than 80% provided that
substantive bias between the groups was unlikely. Other
outcomes from each trial may only be included in the
analysis if available for 80% or more of women.
Data collection, data management and confidentiality
The individual patient data provided by the Collaborators
will be de-identified, re-coded as required and stored in a
custom-designed Microsoft ACCESS database. It will not
include any patient identifying information such as
names or addresses. Electronic data will be located on a
secure, password protected network server. Copies of
hardcopy data will be stored in locked filing cabinets until
converted into electronic format, and will then be securely
destroyed. Only authorised personnel will have access to
the data. All data will be securely stored and archived
according to the policies of the major funder, the Austral-
ian National Health and Medical Research Council.
The data will be checked with respect to range, internal
consistency, consistency with published reports and miss-
ing items. Trial details such as randomisation methods,
and dose and timing of the interventions will be cross-
checked against any published reports, trial protocols and
data collection sheets. Integrity of the randomisation
process will be examined by reviewing the chronological
randomisation sequence and pattern of assignment, as
well as the balance of prognostic factors across treatment
groups (taking into account stratification factors). Incon-
sistencies or missing data will be discussed with the indi-
vidual trialists and attempts will be made to resolve any
problems by consensus. Each trial will be analysed indi-
vidually, and the resulting analyses and trial data will be
sent to the trialists for verification.
Data items requested from the trialists
There has been extensive consultation with the PARIS Col-
laborative Group regarding what data items to collect for
each woman in the analyses. The following section con-
tains the list of data items requested from trialists, which
has been compiled following this consultation. More
detailed definitions for the data items listed below can be
found in Tables 1 and 2. Details of the suggested coding
for each of the following variables can be found in [see
Additional file 2]. A formal request for the provision of
the individual patient data was sent in April 2004 [see
Additional file 3].
a. Characteristics of trials
1 informed consent
2 dates trial opened and closed to accrual
3 total number of women randomised
4 treatments used in each arm of the trial
Table 1: Key definitions for enrolment characteristics
Variable Definition
gestational hypertension de novo systolic BP ≥  140 mmHg and/or diastolic BP ≥  90 mmHg after 20 
weeks' gestation, without proteinuria
severe hypertension systolic BP ≥  160 mmHg and/or diastolic BP ≥  110 mmHg
proteinuria ≥  1+ on dipstick, or ≥  300 mg/24 hours, or spot urine protein/creatinine 
ratio ≥  30 mg/mmol
pre-eclampsia (for women normotensive at trial entry) de novo systolic BP ≥  140 mmHg and/or diastolic BP ≥  90 mmHg after 20 
weeks' gestation with new-onset proteinuria as described above
pre-eclampsia (for women with chronic hypertension at trial entry) new-onset proteinuria as described above
pre-eclampsia (for women with chronic hypertension and proteinuria at 
trial entry)
signs and symptoms of superimposed pre-eclampsia after 20 weeks' 
gestation, for example worsening of hypertension or proteinuria
early onset proteinuria proteinuria as defined above, occurring ≤  33 weeks + 6 days of gestation
early onset pre-eclampsia hypertension and early onset proteinuria as described above
chronic hypertension Essential hypertension: BP ≥  140/90 mmHg pre-conception or in first half 
of pregnancy without an underlying cause, or Secondary hypertension: 
hypertension associated with renal, renovascular, cardiac and endocrine 
disorders
intrauterine growth restriction (IUGR) or small for gestational age (SGA) growth below the 3rd centile, or as defined in the individual trial
miscarriage / fetal death any death in utero
perinatal death death in utero or within the first 7 days of life
neonatal death live born and any reported death within the first 28 daysBMC Pregnancy and Childbirth 2005, 5:7 http://www.biomedcentral.com/1471-2393/5/7
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5 intended duration of treatments
6 definitions of key outcomes used in the trial
7 method of random allocation
8 stratification factors used
9 methods of allocation concealment
b. Characteristics of enrolled women at trial entry
1 unique identifier for the enrolled woman, coded for
anonymity
2 date of randomisation
3 gestational age at randomisation, or best estimate of
expected date of delivery or last menstrual period
4 woman's date of birth or age
5 any previous pregnancy
6 blood pressure (systolic, diastolic, whether diagnosed as
raised)
7 presence of proteinuria
8 presence of oedema
9 risk factors – multiple pregnancy, autoimmune disease,
renal disease, diabetes, chronic hypertension, previous
gestational hypertension or pre-eclampsia/eclampsia
(including early onset disease), family history of preg-
nancy-related hypertensive disorders, previous fetal
growth restriction, previous perinatal death, abnormal
uterine artery Doppler flow and abnormalities on other
diagnostic tests
c. Maternal data items
1 hypertension during pregnancy (highest blood pressure,
diagnosis of severe hypertension)
2 proteinuria during pregnancy (including date and/or
gestation at onset)
3 oedema during pregnancy
4 pre-eclampsia
5 drug treatment for pre-eclampsia or hypertension
6 severe maternal morbidity (including eclampsia, renal
failure, disseminated intravascular coagulation, liver fail-
ure, HELLP syndrome, stroke)
7 onset of labour (spontaneous or induced or pre-labour
caesarean section)
Table 2: Key definitions for outcome measures
Main outcomes Definition
pre-eclampsia as defined in Table 1
pregnancy loss / neonatal death miscarriage, fetal death or death of a liveborn infant before hospital 
discharge
pre-term birth pre-term birth: ≤  37 weeks + 6 days of gestation moderately pre-term birth: 
≤  33 weeks + 6 days of gestation extremely pre-term birth: ≤  27 weeks + 6 
days of gestation
small for gestational age (SGA) infant infant with birth-weight below the 3rd centile, or as defined in the 
individual trial
pregnancy with serious adverse outcome pregnancy with any of the above main outcomes for the woman or any 
fetus/baby, or the death of the woman. If sufficient data available, severe 
maternal morbidity will also be included in this definition.
Other outcomes Definition
early onset pre-eclampsia as defined in Table 1
maternal death death during pregnancy or up to 42 days after termination of the 
pregnancy
antepartum haemorrhage any vaginal bleeding before the onset of labour
placental abruption clear evidence of placental separation
severe maternal morbidity including eclampsia, HELLP syndrome, DIC, pulmonary oedema, liver 
failure, renal failure or CVA/stroke
infant death live born and any reported death from 29 days to 1 year of life or after 
hospital discharge
neonatal bleeding abnormal bleeding in the neonatal period including periventricular 
haemorrhage, gastrointestinal, umbilical or other sitesBMC Pregnancy and Childbirth 2005, 5:7 http://www.biomedcentral.com/1471-2393/5/7
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8 mode of delivery (vaginal, vaginal assisted, caesarean
section)
9 antepartum haemorrhage (all, placental abruption)
10 postpartum haemorrhage and/or estimated blood loss
at delivery
11 maternal mortality
d. Fetal / neonatal / child data items (for each fetus)
1 gestational age at birth and/or date of birth
2 birthweight
3 gender
4 small for gestation age (as defined within each trial:
including centile charts and cut-off point used)
5 miscarriage or stillbirth: date and/or gestational age at
death/loss
6 neonatal or infant death: date and/or age at death
7 admission to special care baby unit or neonatal inten-
sive care unit
8 use of assisted ventilation
9 number of days in hospital or date of hospital discharge
10 neonatal bleeding (for example, periventricular
haemorrhage)
11 child growth and development (such as cerebral palsy,
blindness, deafness, significant cognitive delay – as
defined within each trial)
Planned analyses
This section contains a summary of the planned analyses.
The full, detailed analysis plan will be discussed and
agreed upon by the Collaborators before any data have
been analysed.
Analysis will aim to be of all women ever randomised and
will be based on intention to treat. In the main analyses a
two stage approach will be taken. Outcomes will be ana-
lysed in their original trial and then these separate results
will be combined to give an overall measure of effect. A
fixed effect model will be used and the assumption of
homogeneity of treatment effects will be tested using the
chi squared test. The I2 statistic will also be used to assess
consistency of results.
1. Outcomes to be analysed
The main analyses comparing the effect of antiplatelet
agents with placebo or no antiplatelet agents will be
undertaken for all outcomes listed below, for the woman
and any fetus/baby. The planned sub-group and
sensitivity analyses will be restricted to the designated
main outcomes listed as follows:
a. Main outcomes
• pre-eclampsia
• pregnancy loss / neonatal death
• pre-term birth
• small for gestational age infant
• pregnancy with serious adverse outcome
b. Other outcomes
• early onset pre-eclampsia
• maternal death
• severe maternal morbidity
• antepartum haemorrhage
• placental abruption
• induction of labour
• Caesarean section delivery
• postpartum haemorrhage
• gestation at delivery
• infant admission to special care or neonatal intensive
care unit
• infant required assisted ventilation
• neonatal bleeding
• infant death
2. Planned sub-group analyses
The planned sub-group analyses will be restricted to the
designated main outcomes unless there are clear indica-
tions for expanding the analyses further.
a. Trial-level characteristics
The effect of antiplatelet therapy may vary across the trials
in the meta-analysis because they have used differentBMC Pregnancy and Childbirth 2005, 5:7 http://www.biomedcentral.com/1471-2393/5/7
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agents in different ways. To explore this further, analyses
are planned whereby trials will be grouped according to
the agent used and by dose. These analyses will focus on
the main outcomes. Trials will be classified into subsets
based on the following:
(i) type of antiplatelet(s)
Trials will be grouped by the type of antiplatelet agent (tri-
als that used aspirin alone, trials that used other antiplate-
let agents, trials that used both aspirin and other
antiplatelets agents) given as the active treatment.
(ii) daily dose of aspirin
In trials that used aspirin alone, trials will be grouped by
planned aspirin dose (<75 mg, 75–149 mg, ≥  150 mg).
b. Patient-level characteristics
One of the strengths of individual patient data reviews is
that it allows us to assess eligibility and outcome using
individual women's characteristics. Subgroup analyses
will explore whether any particular risk factors act as effect
modifiers. That is, are there any particular types of women
who benefit more or less from antiplatelet agents? These
analyses will take account each individual woman's own
characteristics, rather than relying on summary measures
of the 'average' risk profile of all participants in an individ-
ual trial.
Analyses will be undertaken to explore whether there are
any particular types of women who benefit more or less
from antiplatelet agents based on the following criteria:
(i) risk factor profile for pre-eclampsia at trial entry
Women normotensive at trial entry:
- previous hypertensive disorders of pregnancy: previ-
ous early onset (≤ 33 weeks + 6 days gestation) pre-
eclampsia or eclampsia / previous pre-eclampsia / previ-
ous gestational hypertension / no previous hypertensive
disorders of pregnancy / no previous pregnancy but fam-
ily history of hypertensive disorders of pregnancy / no pre-
vious pregnancy and no family history of hypertensive
disorders of pregnancy
- diabetes: pre-existing diabetes at enrolment / no pre-
existing diabetes at enrolment
- renal disease: pre-existing renal disease / no pre-existing
renal disease
- autoimmune disease: autoimmune disease / no autoim-
mune disease
-  multiple pregnancy: multiple pregnancy / singleton
pregnancy
- maternal age: <20 years / 20–35 years / >35 years. Mater-
nal age may also be analysed as a continuous variable.
- diagnostic test results: abnormal uterine artery Doppler
scan / other diagnostic test abnormalities / no abnormal
diagnostic test results
- previous SGA: previous small for gestational age infant
/ previous infant not small for gestational age / no previ-
ous infant
- primigravida: first pregnancy with no other risk factors /
first pregnancy with one or more risk factors / second or
subsequent pregnancy with one or more risk factors / sec-
ond or subsequent pregnancy with no risk factors
Women with hypertension at trial entry:
-  hypertension:  gestational hypertension / chronic
hypertension
(ii) gestation at trial entry
To determine whether antiplatelet agents are differentially
effective if given earlier in pregnancy and to determine the
magnitude of any difference, gestational age at randomi-
sation will be primarily analysed as a continuous variable
in regression analyses. However, a subgroup analysis with
women classified according to the following categories
may also be performed: <16 weeks, 16–19 completed
weeks, 20–23 completed weeks, 24–27 completed weeks,
≥ 28 weeks gestation. If numbers are insufficient for any
category, categories will be combined.
3. Planned sensitivity analyses
a. To assess whether results are robust to the inclusion or
exclusion of particular types of trials or patients, the fol-
lowing sensitivity analyses will be conducted:
• exclusion of trials that did not use a placebo for the con-
trol group
• exclusion of trials of small size
• exclusion of poor quality trials (assessed by adequacy of
allocation concealment, blinding, completeness of fol-
low-up and other data checking procedures)
b. To assess whether results are robust to different meth-
ods of analysis or different definitions of pre-eclampsia
[38,39], the following sensitivity analyses will be
conducted:
• comparison of analyses using random effects and fixed
effect modelsBMC Pregnancy and Childbirth 2005, 5:7 http://www.biomedcentral.com/1471-2393/5/7
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• comparison of analyses using individual patient data
(IPD) only with analyses using individual patient data
and aggregate data where IPD unavailable
• comparison of analyses using different definitions of
pre-eclampsia
These sensitivity analyses will be carried out for the main
outcomes.
4. Additional analyses
Depending on what data are available, the level of hetero-
geneity encountered and available time a one-stage mod-
eling approach may also be undertaken to further explore
important key outcomes as appropriate.
Ethical considerations
Participants in the individual trials have previously given
informed consent to participate in their respective trial.
The data for this project are to be used for the purpose for
which they were originally collected and are available
through an agreement between all trialists of the PARIS
Collaboration. These trialists remain the custodians of
their original individual trial data at all times. Data are
provided on the stipulation that all trials have received
ethical clearances from their relevant bodies.
Project management
Membership of the PARIS Collaboration will be repre-
sentative(s) from each of the trials contributing data to the
review with an accompanying project coordination and
data management structure as described in this section.
The membership and responsibilities of each of these
management groups is as follows:
a. Steering Group
The Steering Groupwill be responsible for project man-
agement decisions and will meet approximately 4–6 times
per year, usually via teleconference. Membership: D
Henderson-Smart1  (co-chair), L Duley2  (co-chair), L
Askie1 (project coordinator), M Showell1 (project admin-
istrator), B Farrell2, L Stewart3, M Clarke4, J King5, C
Roberts.1 The first six members act as the Secretariat.
1 Centre for Perinatal Health Services Research, University
of Sydney, Australia;
2 Resource Centre for Randomised Trials, University of
Oxford, Oxford, UK;
3 Medical Research Council Clinical Trials Unit, London,
UK;
4 UK Cochrane Centre, Oxford, UK;
5 Royal Women's Hospital, Melbourne, Australia.
b. Advisory Group
The aim of the Advisory Group is to facilitate representa-
tive input from the Collaborative Group to the Steering
Group. Membership of the Advisory Group will include
people who have contributed to the trials included in the
project and other international experts. Each trial that
recruited over 1000 women will be invited to have a rep-
resentative on the Advisory Group. This group will not
have regular meetings, but may be consulted from time to
time by means of email or teleconference, and may have
occasional  ad hoc meetings. Co-chairs of the Advisory
Group: C Redman, C Roberts.
c. Collaborative Group
All potentially eligible trialists will be contacted and
invited to become members of the Collaborative Group.
The corresponding author for each study will be contacted
in the first instance. If there is no response, the associated
statistician, data manager and/or other authors will be
contacted. This process will be updated annually for the
duration of the project, to ensure that new trialists are
offered the opportunity to join the project and contribute
their data.
d. Project coordination centre
The project will be coordinated from the Centre for Peri-
natal Health Services Research (CPHSR), University of
Sydney, NSW, Australia. The coordination centre will be
responsible for the daily management of the project
including correspondence, newsletter production, main-
taining current trialist contact information and meeting/
teleconference organisation.
e. Data management centre
The data management centre, based at the UK Cochrane
Centre, will be responsible for the receipt, storage, and
analysis of project data as directed by the Collaborative
Group via the Steering Group.
f. Collaborators' meetings
All members of the Collaboration, including the Steering
Group, the Advisory Group, and representatives of each
participating trial, will be invited to attend regular Collab-
orators' meetings. These meetings will be scheduled,
where possible, to coincide with the biennial
International Society for the Study of Hypertension Preg-
nancy (ISSHP) congresses. The meetings will be designed
to allow maximum input from the participating trialists
into the design, conduct, analysis and reporting of the
project's results. The final Collaborators' meeting, at
which the results will be presented for discussion, is
scheduled for 2006 in Oxford, UK. The discussion at this
meeting will provide the basis for the paper publication.BMC Pregnancy and Childbirth 2005, 5:7 http://www.biomedcentral.com/1471-2393/5/7
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Funding
The National Health and Medical Research Council
(NHMRC) of Australia have provided funding for the
project through the Centre for Perinatal Health Services
Research, University of Sydney. These funds are: a three
year project grant (ID: 253636) for the overall project
administration base in Sydney, and a Sidney Sax Public
Health Postdoctoral Fellowship (ID: 245521), based in
Oxford and Sydney. Additional support is being provided
by the Resource Centre for Randomised Trials and the UK
Cochrane Centre, located in Oxford, UK, and the Medical
Research Council Clinical Trials Unit in London, UK.
Publication policy
The results of the project's analyses will be presented to,
and discussed with, the Collaborative Group before pub-
lication. The aim of publication will be presentation of
the results, rather than their interpretation. The main
manuscript will be prepared by the Secretariat, and then
circulated to the Steering and Advisory Groups for com-
ment and revision. The revised draft paper then will be cir-
culated to all members of the Collaborative Group for
comment before publication. All publications using these
data will be authored in the name of the PARIS Collabo-
ration, as follows: Perinatal Antiplatelet Review of Inter-
national Studies (PARIS) Collaboration.
Discussion
Despite good evidence that antiplatelet agents (princi-
pally low dose aspirin) reduce the incidence of pre-
eclampsia and its consequences, such as preterm birth and
perinatal mortality, uncertainty remains regarding
whether some women (in terms of risk) benefit more than
others, when in pregnancy treatment should ideally start,
and whether treatment effectiveness is dependent on
antiplatelet dose.
The best way to answer these questions is to utilise exist-
ing individual patient data from all women enrolled in tri-
als that have addressed this question. This approach has
been described as the 'gold standard' of systematic review
methodology as it allows for more powerful and flexible
analysis of both subgroups and outcomes.
The PARIS Collaboration has been formed to undertake a
systematic review of all available trials, with meta-analysis
based on individual patient data, to answer these impor-
tant clinical questions. This will be the first individual
patient data review in the perinatal field. Provision of data
by the participating Collaborators commenced in 2004,
and results will be ready for presentation in 2006. Follow-
ing consultation and discussion with the Collaborative
Group, the main publication is expected in early 2007.
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